• Mepal Final Logo 628X461
    Mepal
    Benelux / Private Equity

    Consumer & Private Label

    Overview

    Mepal is a leading Dutch lifestyle consumer brand known for its innovative, high-quality, and sustainable products for storing, serving, and take-away of food and drinks. 

    Headquartered in Lochem, the Netherlands, Mepal's products are renowned for their original and premium design, functionality, convenience, quality, and sustainability. 

    The company has experienced impressive growth since 2018, driven by organic expansion into food retail and other large retail chains in Germany and increased e-commerce revenue.

    Highlights

    • Strong track record in both innovation and design, winning numerous leading design awards
    • Further growth planned in existing core markets of the Netherlands, Belgium and Germany as well as developing new markets in Europe
    • Planned growth of its online business, further benefitting from increased e-commerce opportunities
    • Strong focus on ESG and received B-Corp certification in 2024. Mepal is focused on increasing the share of recyclable materials in the production process and customers can re-order parts to extend the lifecycle of their products. Additionally, the products themselves help reduce food waste and the usage of single-use packaging, such as plastic bags and single-use cups and bottles 
    • Differentiates itself from the competition based on premium design, functionality, product quality and a history of innovations (both re-designing existing concepts and launching new product lines)

    Regulatory information 
    This transaction involved a recommendation of 3i Investments plc, advised by 3i Benelux.

  • Mpm Logo
    MPM
    UK / Private Equity

    Consumer & Private Label

    Overview

    MPM is an international leader in branded, premium, natural pet food. The business owns leading pet food brands such as Applaws, Encore, and Reveal and differentiates itself through its high quality, human-grade products, its natural, clean-label ingredients, and its “cat first” proposition.

    MPM is a certified B-Corp, and its loyal customer base places great importance on its sustainable sourcing and recyclable packaging. Headquartered in Manchester, UK, MPM has an established presence in the UK, EMEA, and APAC with a fast-growing business in North America resulting in international sales now accounting for more than 70% of revenues.

    The market has proven resilient through economic downturns and Covid-19, with pet ownership increasing amongst a highly engaged and loyal community for whom pets are seen as family members.

    Highlights

    • The premium wet cat food market is large and is forecast to continue to grow at c.7% p.a.
    • MPM fits well with our desire to invest in strong mid-market businesses where we see significant headroom to accelerate international expansion
    • We invested £125m alongside management for a majority stake in this rapidly growing, resilient business
    • Strong relationships with key retailers across pet specialist, grocery and online channels
    “3i has a formidable track record in helping its companies to grow internationally, particularly in the US market. This will be especially key for MPM as we look to accelerate our expansion in North America. The 3i team also has significant brand expertise through a number of its consumer investments which will be of great benefit to MPM.” Julian Bambridge, CEO, MPM

    Regulatory information 
    This transaction involved a recommendation of 3i Investments plc, advised by 3i Investments plc.

  • Q Holding Company
    Q Holding
    North America / Private Equity

    Healthcare

    Overview

    Q Holding is a global leading manufacturer of catheters and high-end materials science-based critical components and subassemblies for the medical devices industry. Headquartered in Ohio, it sells products in over 80 countries and has 13 manufacturing locations in North America, Europe, and Asia. 

    Q Holding has built a strong reputation as the supplier of choice to provide high-quality components that are mission critical. It has developed longstanding relationships with a broad range of blue-chip customers who value their ability to develop such critical products and solutions.

    Highlights

    • Acquisitions of Degania Medical (Dec. 2016), a leading global manufacturer of catheters and other medical devices and Silicone Altimex (July 2015), a silicone provider of medical device components and pharmaceutical assemblies
    • Focused on achieving significant organic growth, driven by its differentiated product offering, high service levels and a strong end-market
    • Experienced management team with longstanding track record of driving innovation in product and service offering
    • Sale of Q Holding’s QSR division, a leading developer and manufacturer of electrical connector seals, for $625m
    • Sale of Precision Components Division, a leading provider of silicone and elastomeric molding and extrusion capabilities, for c.$172m

    Regulatory information 
    This transaction involved a recommendation of 3i Corporation. 

  • Royal Sanders Resized3
    Royal Sanders
    Benelux / Private Equity

    Consumer & Private Label

    Overview

    Royal Sanders is a leading European private label and contract manufacturing producer of personal care products. Its key geographies are the Benelux, Germany, France and the UK with plants in the Netherlands (Vlijmen and Zeewolde), the UK (Bradford), Belgium (Ieper) and Germany (Groß-Rohrheim, Waiblingen and Jessenitz). 

    Main product categories include shampoo, bath and shower gels, body lotions and hand wash. The company sells its products through private label, contract manufacturing and own brands including Van Gils, Sanicur and Odorex.

    3i is investing alongside management to drive the company’s international growth strategy.

    Highlights 

    • Demonstrated a consistent and strong track record of profitable organic growth over the past 10 years, significantly outgrowing the market
    • Completed seven add – on acquisitions since 2018
    • Production footprint expanded from two to seven locations in the Netherlands, Belgium, UK and Germany
    • Differentiates itself through its focus on quality and service, longstanding relationships with key customers and superior operational capabilities at its state-of-the-art facilities
    • Successfully driving consolidation in a fragmented industry with 6 completed acquisitions to date and multiple further potential buy-and-build opportunities across geographies

     

    We are delighted to be partnering with 3i. It has extensive experience in buy-and-build in private label, for example through its investment in European soft drinks bottler Refresco, and in growing companies internationally through its network of valuable industry experts in the consumer sector. Bart Hullegie, CEO, Royal Sanders

    Regulatory information 
    This transaction involved a recommendation of 3i Investments plc, advised by 3i Benelux.

  • Sanisure 500X367
    SaniSure
    North America / Private Equity

    Healthcare

    Overview

    3i has established a scaled, global, pure-play platform in the bioprocessing market by bringing together SaniSure, Cellon, TBL, and Silicone Altimex (together, “SaniSure”). SaniSure is a vertically-integrated player in the single-use bioprocessing technology (“SUT“) space capable of providing highly customised and innovative solutions to leading biopharma and biotech customers. The SUT bioprocessing market is anticipated to grow at 13-20%+ across its various subsegments over the coming years, as the industry transitions to more flexible, clean, and operating cost-advantaged technology relative to traditional multi-use counterparts.

    Recognising an attractive market opportunity characterised by high growth and a need for a leading independent platform of scale, 3i began a journey to create a single-use bioprocessing platform in December 2019 with the acquisition of founder-owned Cellon and subsequent combination of the business with Silicone Altimex and TBL Performance Plastics.

    In July 2020, the platform completed the transformative acquisition of founder-owned Sani-Tech West Inc., a leading US-based manufacturer, distributor, and integrator of SUT systems and components, helping the platform accelerate its US market strategy.

    The acquisition significantly expanded the combined group’s global footprint and brought a complementary portfolio of innovative products and single-use solutions capabilities. The combined platform has robust manufacturing and cleanroom assembly operations in both North America and Europe, offering enhanced supply chain assurance to its customers with a global footprint and vertically-integrated capabilities. 

    Highlights

    • Created a unified, vertically-integrated platform in the high-growth bioprocessing space by bringing together Cellon, TBL, and Silicone Altimex 
    • Recruited key management members to complement the founders and other existing leaders, while professionalising the organisation and codifying business strategy
    • Brought Sani-Tech West into the platform, doubling the size of the combined business and creating a global leader with well-established operations and reach in North America and Europe
    • Positioned the platform to be a global strategic SUT solutions partner of choice for leading biopharma and biotech companies and contract development and manufacturing organisations (“CDMOs”)
    • SaniSure received the EcoVadis Silver Medal 2024 for its sustainability practices. The Silver rating recognises SaniSure’s proactive efforts to reduce its environmental impact throughout its operations, the company's commitment to implementing robust environmental, social and governance programmes and its focus on achieving even higher sustainability targets in the future.

    Regulatory information 
    This transaction involved a recommendation of 3i Corporation.

  • Ten23 Logo Cropped 500X367
    ten23 health
    North America / Private Equity

    Healthcare

    Overview

    ten23 health was founded in 2021 and is a development, manufacturing and testing company for biotech start-ups and the established pharmaceutical industry.

     

    Highlights

    • Partnering with a highly experienced team of experts, including Prof. Dr Hanns Christian Mahler, with a proven track record in pharmaceutical product design and development
    • As drug development activities across biologics modalities continue to accelerate, small biotechs and large pharma companies will increasingly outsource key services which require unique and market tested expertise
    • ten23 health will deliver services in an engrained, fair and sustainable manner, respecting the future of the planet and people’s health
    • Supported ten23’s acquisition of swissfillon, a leader in the sterile filling of complex pharmaceuticals into innovative containers and devices, creating a vertically integrated CDMO with ten23’s Basel development lab and swissfillon’s scaled fill & finish manufacturing

    "3i’s demonstrated knowledge and deep understanding of the biotech landscape made them a clear partner in building ten23 health into a leader in the development, manufacturing and testing of injectable medicines.” Prof. Dr. Hanns-Christian Mahler, CEO ten23 health

    Regulatory information 
    This transaction involved a recommendation of 3i Investments plc.

  • Vakdiscount Logo
    VakantieDiscounter
    Benelux / Private Equity

    Consumer & Private Label

    Overview

    VakantieDiscounter is a leading, technology-enabled online travel agency in the Benelux focused on affordable holidays, providing the best-value holiday deals. 

    Headquartered in Amsterdam, the Netherlands, VakantieDiscounter is the number one online holiday packages platform in the Benelux.  Through its own pre-packaged holidays as well as those of third-party providers, VakantieDiscounter offers more than 1.3 billion holiday package combinations in over 50 countries with more than 17,000 accommodation options.

    Highlights

    • We recruited new Chair, Vagn Sørensen (a highly experienced Chair of PE businesses, especially in travel), and NXD Alistair Daly (former CMO of OnTheBeach), to drive the company’s next phase of growth 
    • Broad package offering and value-for-money focus has created a winning proposition which has grown market share rapidly 
    • Highly scalable, technology-driven business with a strong position in the market and a highly capable management team
    • Our investment helps ensure the company has the resources to sustain market leadership and navigate the current economic environment from a position of strength
    "I am excited to be partnering with the team at 3i. Customers will benefit from continued investment in our travel platform. 3i’s experience in the value-for-money consumer segment and travel sector makes them the ideal partner to scale our business and take advantage of the opportunity to further grow our market share by delivering great value to travellers." Hans van Hoffen, CEO, VakantieDiscounter

    Regulatory information 
    This transaction involved a recommendation of 3i Investments plc, advised by 3i Benelux.

  • Wilsonhcg 500X367
    Wilson Human Capital Group
    North America / Private Equity

    Services & Software

    Overview

    Wilson Human Capital Group (“WilsonHCG”) is an award-winning global leader in talent solutions. Headquartered in Tampa, Florida, WilsonHCG is a global business with offices throughout North America, Europe and Asia and has operated as a strategic partner to some of the world’s most admired brands in helping them plan and execute on talent acquisition globally. The company provides a full suite of configurable talent solutions including recruitment process outsourcing (“RPO”), executive search, contingent talent solutions and talent consulting.

    WilsonHCG is widely known for its high-performance culture including its core values of collaboration, ownership, integrity, passion and communication. As a result, the company is recognised as a leader by various industry trade associations such as HRO Today, Everest Group, NelsonHall and SIA, including leading the HRO Today Baker’s Dozen Top RPO rankings in recent years.

    Highlights

    • Double-digit historic annual growth within its RPO sector, WilsonHCG’s core area of focus.
    • The RPO market is expected to benefit following the Covid-19 pandemic as companies increasingly value the superior outcomes, flexibility and efficiency that RPO providers such as WilsonHCG provide their clients.
    • WilsonHCG is a strong fit within 3i’s investment strategy, with a focus on high quality outsourced services, an increasingly international business, especially across Europe and Asia, and a strong management team.
    “We have known the 3i team for a number of years and they have demonstrated a clear commitment to investing in our space. There is a strong cultural fit between our organisations and a shared ambition to continue building WilsonHCG into the global talent solutions leader. Further, 3i’s international network will enable us to continue expanding our already global footprint." John Wilson, Founder and CEO, WilsonHCG

    Regulatory information 
    This transaction involved a recommendation of 3i Corporation.

  • Xsuite Crop
    xSuite
    Germany / Private Equity

    Services & Software

    Overview

    xSuite is a leading accounts payable process automation specialist focused on the SAP ecosystem. Headquartered in Ahrensburg, Germany, xSuite specialises in software applications for Accounts Payable Invoice Automation (“APIA”), which enable customers to digitalise, streamline and automate invoice processing, helping them to reduce costs, drive efficiencies and improve quality. With over 290 employees in Germany, Denmark, the Netherlands, Singapore, Slovakia, Spain and the US, xSuite develops additional workflows and integration capabilities specific to the SAP ecosystem.

    With our global network of experts, we are supporting xSuite to build on its emerging presence in the US market and scale its North American operations. In addition, we are partnering with management to accelerate the transition to more subscription software revenues as well as leveraging commercial best-practices recently implemented across our other portfolio companies.

    Highlights

    • High customer satisfaction given the company’s industry-leading technological capabilities and strong service levels
    • xSuite has a growing presence in the US where it has won several blue-chip clients such as Dole, Lionsgate and Crocs and is scaling rapidly 
    • APIA market is growing with forecasts of +10% CAGR driven by the digitisation of workflows and a focus on reducing labour costs.
    • Growth driven by increasing invoice volumes, adoption of automation solutions, expansion in the use cases of these solutions and the transition to specialist applications.
    “3i is a natural fit for us given their extensive experience of international growth strategies and their deep sector expertise. We are excited to be working with them to bring xSuite’s offering to a wider audience.” Matthias Lemenkühler, CPTO, xSuite

    Regulatory information 
    This transaction involved a recommendation of 3i Investments plc, advised by 3i Germany.

  • Yanga Logo Portfolio
    Yanga
    Benelux / Private Equity

    Consumer & Private Label

    Overview

    Yanga is the leading provider of an integrated in-house sports drinks concept to fitness chains.  Headquartered in the Netherlands, Yanga sells flavoured sports drinks through its installed base of proprietary hydration stations in gyms across Europe. Gym members who have an add-on or premium membership can use the stations to get flavoured water with sugar and colorant-free syrups during their workouts.

    3i is investing to support its international growth and expansion into North America.

    Highlights

    • Unique offering at scale with an installed base of >2,500 hydration stations
    • Strongly differentiated business model, delivering a win-win proposition to fitness operators and gym members
    • Exposed to key trends in the fitness market, including value-for-money and increased industry consolidation

    Regulatory information 
    This transaction involved a recommendation of 3i Investments plc, advised by 3i Benelux.

  • Ydeon Logo
    YDEON
    Germany / Private Equity

    Consumer & Private Label

    Overview

    YDEON headquartered in Hamburg, Germany, is the online leader in the garden homes, sheds, saunas and related projects market in the DACH region. The business combines specialist trade product know-how with digital competence and offers a one-stop platform for customers – from planning to realisation and maintenance of their garden and home projects.

    Founded in 2002, YDEON is a pure eCommerce player and has been the pioneer in selling garden homes directly to consumers.   

    We see the business as the foundation to building the leading European platform for home and garden projects. The key focus is to develop the product range into adjacent categories, as well as to internationalise the business by expanding into neighbouring countries.

    Highlights

    • The home and garden market is expected to see online penetration further increase.
    • YDEON generates 95% of its sales directly online with a high level of SEO traffic as a result of its strong content
    • The business differentiates itself through its own product development, excellent customer service, and the management of complex logistics
    • Only 70 days after 3i's acquisition, YDEON acquired Polhus, a leading online retailer of garden houses and related products in Scandinavia
    • Acquisition of Outdoors Toys, a leading online D2C retailer of outdoor garden toys in the UK, in October 2021
    “3i has a great reputation for helping its companies to grow internationally and we are excited to partner with their team at this point in our journey. The 3i team has a strong network, excellent digital capabilities and a strong track record in the consumer retailer space, all of which will be of great benefit to YDEON.” Sebastian Arendt, CEO, YDEON

    Regulatory information 
    This transaction involved a recommendation of 3i Investments plc, advised by 3i Germany.

Back to top